Company intelligence / Profile preview

IN3BIO

Glasgow, Scotland, United Kingdomin3bio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

IN3BIO's lead cancer vaccine program (IN01) is in Phase I/II clinical trials for colorectal cancer, targeting mutant KRAS, NRAS, or BRAF tumors. Previous studies in NSCLC with their platform showed a median progression-free survival of 17.5 months versus 11 months for EGFR tyrosine kinase inhibitor alone, indicating improved outcomes. Other preclinical programs target additional growth factors implicated in cancer progression.

Therapeutic areas: Infectious DiseasesOncology
Modalities: VaccineRecombinant proteinBiologic
Industry: Biotech

Drug pipeline

1 asset

IN01

Phase 1

Indications: Colorectal cancer, Non-small cell lung cancer

Partnerships

3P Biopharmaceuticals

Beyond the preview

Go deeper on IN3BIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN3BIO.

Explore the full profile